河北中医
河北中醫
하북중의
HEBEI JORNAL OF TRADITIONAL CHINESE MEDICINE
2014年
12期
1812-1814
,共3页
二至丸%抗病毒药%肝炎,慢性%中西医结合疗法
二至汍%抗病毒藥%肝炎,慢性%中西醫結閤療法
이지환%항병독약%간염,만성%중서의결합요법
Erzhi pill%Antiviral drugs%Hepatitis%Chronic%Combine traditional Chinese and western medi-cine therapy
目的：观察二至丸联合阿德福韦酯治疗慢性乙型病毒性肝炎（以下简称慢性乙肝）的疗效和不良反应。方法将60例慢性乙肝患者随机分为2组，对照组30例予阿德福韦酯治疗，治疗组30例在对照组治疗基础上加二至丸，2组均连续治疗144周。观察2组患者在治疗48、96、144周时尿隐血、血肌酐发生情况，比较2组丙氨酸氨基转移酶（ ALT）复常率、尿隐血发生率、血肌酐异常率、乙肝病毒脱氧核糖核酸（ HBV-DNA）阴转率及阿德福韦酯耐药发生率。结果2组患者均未发现血肌酐升高。治疗组治疗48、96及144周时，ALT复常率均高于对照组同期（P＜0．05）；96、144周时，尿隐血发生率低于对照组同期（P＜0．05）；治疗期间2组HBV-DNA阴转率及阿德福韦酯耐药发生率比较差异无统计学意义（ P＞0．05）。结论二至丸联合阿德福韦酯治疗慢性乙肝不能协助控制病毒复制和防止阿德福韦酯耐药的发生，但可有效提高肝功能复常率和预防阿德福韦酯潜在的肾毒性。
目的：觀察二至汍聯閤阿德福韋酯治療慢性乙型病毒性肝炎（以下簡稱慢性乙肝）的療效和不良反應。方法將60例慢性乙肝患者隨機分為2組，對照組30例予阿德福韋酯治療，治療組30例在對照組治療基礎上加二至汍，2組均連續治療144週。觀察2組患者在治療48、96、144週時尿隱血、血肌酐髮生情況，比較2組丙氨痠氨基轉移酶（ ALT）複常率、尿隱血髮生率、血肌酐異常率、乙肝病毒脫氧覈糖覈痠（ HBV-DNA）陰轉率及阿德福韋酯耐藥髮生率。結果2組患者均未髮現血肌酐升高。治療組治療48、96及144週時，ALT複常率均高于對照組同期（P＜0．05）；96、144週時，尿隱血髮生率低于對照組同期（P＜0．05）；治療期間2組HBV-DNA陰轉率及阿德福韋酯耐藥髮生率比較差異無統計學意義（ P＞0．05）。結論二至汍聯閤阿德福韋酯治療慢性乙肝不能協助控製病毒複製和防止阿德福韋酯耐藥的髮生，但可有效提高肝功能複常率和預防阿德福韋酯潛在的腎毒性。
목적：관찰이지환연합아덕복위지치료만성을형병독성간염（이하간칭만성을간）적료효화불량반응。방법장60례만성을간환자수궤분위2조，대조조30례여아덕복위지치료，치료조30례재대조조치료기출상가이지환，2조균련속치료144주。관찰2조환자재치료48、96、144주시뇨은혈、혈기항발생정황，비교2조병안산안기전이매（ ALT）복상솔、뇨은혈발생솔、혈기항이상솔、을간병독탈양핵당핵산（ HBV-DNA）음전솔급아덕복위지내약발생솔。결과2조환자균미발현혈기항승고。치료조치료48、96급144주시，ALT복상솔균고우대조조동기（P＜0．05）；96、144주시，뇨은혈발생솔저우대조조동기（P＜0．05）；치료기간2조HBV-DNA음전솔급아덕복위지내약발생솔비교차이무통계학의의（ P＞0．05）。결론이지환연합아덕복위지치료만성을간불능협조공제병독복제화방지아덕복위지내약적발생，단가유효제고간공능복상솔화예방아덕복위지잠재적신독성。
Objective To investigate the effect of chronic viral hepatitis treated by combination of Erzhi pill and adefovir dipivoxil.Methods 60 cases of chronic viral hepatitis were randomly divided into two groups.30 pa-tients in control group were treated by adefovir dipivoxil.30 cases in treatment group were treated by combination of Erzhi pill and adefovir dipivoxil.The therapeutic course was 144 weeks in two groups.The prevalence of urine occult blood and serum creatinine in two groups were observed in the treatment of 48,96,144 weeks.Alanine aminotrans-ferase (ALT) recovery rate,incidence of urine occult blood,serum creatinine abnormal rate,hepatitis b virus DNA ( HBV-DNA) negative rate and adefovir resistance incidence were compared in two groups.Results There was no increase of serum creatinine level in two groups of patients.ALT recovery rate of the treatment of 48,96,144 weeks in treatment group was higher than that in control group (P<0.05).Incidence of urine occult blood 96 and 144 weeks in treatment group was lower than that in control group (P<0.05).There was no significant difference between two groups on HBV-DNA negative rate and adefovir resistance incidence (P>0.05).Conclusion Combination of Erzhi pill and adefovir ester on chronic viral hepatitis can′t help control viral replication and prevent adefovir ester re-sistance,but can effectively improve liver function recovery rate and prevent adefovir ester potential renal toxicity.
